Doxorubicin Market – Growth Market Reports

The global doxorubicin market size is estimated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising government initiatives, growing investment in advanced technology in clinical oncology such as intravenous therapy and digital microfluidics for on chip biological analysis.

Doxorubicin is an anthracycline antibiotic for anti-cancer chemotherapy drugs, rubex and adriamycin. It is produced from a natural substance produced by the bacteria Streptomyces peucetius var. caesius and belongs to the antineoplastic class of anti-cancer medications. Breast, ovary, stomach, bone, bladder, testicles, lung, osteogenic sarcoma, soft tissue, Wilms' tumor, and Hodgkin's & non-lymphomas Hodgkin's are among the area of cancers for which doxorubicin is used for the treatment. It is also utilized in the treatment of squamous cell carcinomas of the head and neck less commonly.

Furthermore, doxorubicin intercalates between the base pairs in the deoxyribonucleic acid (DNA) helix, blocking DNA replication, decreasing protein synthesis, and reduces the rate of growth of malignant cells. This drug is delivered intravenously using peripheral inserted central line catheters or central venous catheters and is available in injectable solution & lyophilized powder form. The amount of this medicine is determined by the type and severity of cancer as well as the type of other medications used during therapy.

According to the American Cancer Society (ACS), it was reported that about 38 million people die every year due to non-communicable diseases, with more than 8 million of them are dying from tumor malignancy. Furthermore, based on the estimates of the World Health Organization (WHO), the cancer incidence rate could further increase by 50% by 2020. The rising use of the drug to treat AIDS related Kaposi Sarcoma, breast malignancy, multiple myeloma, and acute meroblastic leukemia are the pivotal factors expected to boost the doxorubicin market value.

Market Trends, Drivers, Restraints, and Opportunities

Increasing application of doxorubicin and rising number of companies manufacturing doxorubicin are expected to fuel the market growth.
Rising geriatric population across the world is another factor of growing prevalence of blood cancer. This is expected to boost the market growth in the coming years.
Development of pre-clinical and clinical research along with the advancement in therapeutics coupled with the presence of robust product pipeline are anticipated to drive market growth.
Formation of new rules and regulations from government bodies encouraging for the development of new drugs for blood cancer are estimated to propel the market.
Less awareness among the people related to different types of cancers is another key challenge that can hinder the market growth during the forecast period.
Increasing expenditures and high cost investment in the treatment process are likely to hamper the market growth.
Early stage approval from regulatory bodies for cancer treatment drugs is projected to be a great opportunity for pharmaceutical companies in near future. This is estimated to upsurge the market growth.

Key Players

Cadila Pharmaceuticals
Sun Pharmaceutical Industries Ltd.
SRS Pharmaceuticals Pvt. Ltd.
Pfizer, Inc.
Cipla, Inc.
Johnson & Johnson
Zydus Cadila

Competitive Landscape

Some of the key players competing in the market are Cadila Pharmaceuticals; Sun Pharmaceutical Industries Ltd., SRS Pharmaceuticals Pvt. Ltd.; Pfizer, Inc.; and Cipla, Inc. Key players in the doxorubicin market are focusing on marketing strategies such as expansion of their product portfolio, merger & acquisition, and collaboration & partnerships by offering latest version of devices to gain substantial share in the market. New competitors in the market are focusing on advanced and affordable alternatives to existing products in order to take advantage of the market potential available in the developing countries. For example, Aeterna Zentaris announced in 2015 that patient enrollment for the ZoptEC phase 3 clinical study with Zoptarelin Doxorubicin for advanced endometrial cancer cases had been completed.

To Get a New Sample Request: https://growthmarketreports.com/request-sample/2347

Contact Us